TY - JOUR
T1 - The rediscovery of DON (6-diazo-5-oxo-L-norleucine).
AU - Kisner, D. L.
AU - Catane, R.
AU - Muggia, F. M.
PY - 1980
Y1 - 1980
N2 - DON (6-diazo-5-oxo-L-norleucine) and azotomycin are glutamine antagonists that were tested in human malignancies in the 1950s. Azotomycin demonstrated significant activity in colorectal cancer. DON is probably the active form of azotomycin. Recent impressive results for both of these agents in human tumor xenografts (especially the CX-2 colon tumor) have stimulated renewed clinical interest in DON, the more readily available agent. DON mechanism of action, clinical pharmacology, previous clinical data, and current phase I studies are discussed.
AB - DON (6-diazo-5-oxo-L-norleucine) and azotomycin are glutamine antagonists that were tested in human malignancies in the 1950s. Azotomycin demonstrated significant activity in colorectal cancer. DON is probably the active form of azotomycin. Recent impressive results for both of these agents in human tumor xenografts (especially the CX-2 colon tumor) have stimulated renewed clinical interest in DON, the more readily available agent. DON mechanism of action, clinical pharmacology, previous clinical data, and current phase I studies are discussed.
UR - http://www.scopus.com/inward/record.url?scp=0019245398&partnerID=8YFLogxK
U2 - 10.1007/978-3-642-81488-4_30
DO - 10.1007/978-3-642-81488-4_30
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:0019245398
SN - 0080-0015
VL - 74
SP - 258
EP - 263
JO - Recent Results in Cancer Research
JF - Recent Results in Cancer Research
ER -
